COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech (OTCQB: CBBT) today announced that the company intends to initiate the search process to partner with a Contract Research Organization (CRO). The search comes as Cerebain readies itself for clinical trials and the FDA application process in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
“When working with CROs, entry into drug development has become immensely simplified, as the need for companies, such as ours, to do everything ‘in house’ is now redundant,” stated Eric Clemons, President and CEO of Cerebain. “CROs that specialize in clinical-trials services can offer their clients the expertise of moving a new device from its conception to FDA marketing approval, without the client having to maintain a staff for these services.”
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.